Role of RANKL in bone diseases

Trends in Endocrinology and Metabolism

Volumn 20, Issue 2, 2009, Pages 88-94

  Anandarajah, Allen P ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMGN 0007; ANTIRHEUMATIC AGENT; DENOSUMAB; ESTROGEN; IMMUNOGLOBULIN FC FRAGMENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; BONE METASTASIS; BONE REMODELING; CLINICAL TRIAL; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; HUMAN; JOINT DESTRUCTION; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS; BONE DISEASES; BONE REMODELING; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 63749095471     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2008.10.007     Document Type: Review

References (63)

1. Anderson D.M., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic cell function. Nature 390 (1997) 175-179
2. Blair J.M., et al. RANK ligand. Int. J. Biochem. Cell Biol. 39 (2007) 1077-1081
3. Lacey D.L., et al. Osteoprotegerin ligand is a cytokine that regulated osteoclast differentiation and activation. Cell 93 (1998) 165-176
4. Kartsogiannis V., et al. Localization of RNAKL (receptor activator of NFkB ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 25 (1999) 525-534
5. Eghbali-Fatourechi G., et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 111 (2003) 1221-1230
6. Hofbauer L.C., et al. Effects of immunosuppression on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem. Biophys. Res. Commun. 280 (2001) 334-339
7. Theoleyre S., et al. The molecular triad OPG/RANK/ RANKL involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 15 (2004) 457-476
8. Glass D.A., et al. Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8 (2005) 751-764
9. Schneeweis L.A., et al. Functional dissociation of osteoprotegerin and its interaction with receptor activator of NF-κB ligand. J. Biol. Chem. 280 (2005) 41155-41164
10. Naito A., et al. Severe osteopetrosis, defective interleukin-1 signaling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4 (1999) 353-362
11. Boyce B.F., and Xing L. Biology of RANK, RANKL and osteoprotegerin. Arthritis Res. Ther 9 (2007) S1-S7
12. Wong B.R., et al. TRANCE, a TNF family member, activates Akt/ PKB through a signaling complex involving TRAF-6 and c-Src. Mol. Cell 4 (1999) 1041-1049
13. Hotokezaka H., et al. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J. Biol. Chem 277 (2002) 47366-47372
14. David J.P., et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J. Cell Sci. 115 (2002) 4317-4325
15. Masumoto M., et al. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J. Biol. Chem. 275 (2000) 31155-31161
16. Wada T., et al. The molecular scaffold Gab2 is a critical component of RANK signaling and osteoclastogenesis. Nat. Med. 11 (2005) 394-399
17. Lacey D.L., et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 157 (2000) 435-448
18. Kong Y.Y., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis. Nature 397 (1999) 315-323
19. Hofbauer L.C., and Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA 292 (2004) 490-495
20. Jones D.H., et al. Role of RANKL and RANKL in bone loss and arthritis. Ann. Rheum. Dis. 61 (2002) ii32-ii39
21. Riggs B.L., et al. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23 (2002) 279-302
22. Manolagas S.C., et al. Sex steroids and bone. Recent Prog. Horm. Res. 57 (2002) 385-409
23. Miyazaki T., et al. Changes in receptor activator of nuclear factor kB and its ligand, osteoprotegerin, bone type alkaline phosphatase and tartrate resistant acid phosphatase in ovariectomized rats. J. Cell. Biochem. 93 (2004) 503-512
24. Kearns A.E., et al. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 29 (2008) 155-192
25. Schett G., et al. Soluble RANKL and risk of nontraumatic fracture. JAMA 291 (2004) 1108-1113
26. Eghbali-Fatourechi G., et al. Role of RANKL ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 111 (2003) 1221-1230
27. D'Amelio P., et al. Estrogen deficiency increases osteolcastogenesis up regulating T cells activity: a key mechanism in osteoporosis. Bone 43 (2008) 92-100
28. Schett G., et al. Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum. 52 (2005) 3192-3201
29. Redlich K., et al. Osteoclasts are essential for TNF-medicated joint destruction. J. Clin. Invest. 110 (2002) 1419-1427
30. Pettit A.R., et al. TRANCE/ RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 159 (2001) 1689-1699
31. Li P., et al. RANKL signaling is not required for TNF-mediated increase in CD11 (hi) osteoclast precursors but is essential for mature osteoclast formation in TNF-alpha mediated inflammatory arthritis. J. Bone Miner. Res. 19 (2004) 207-213
32. Kotake S., et al. Activated human T cells directly induce osteoclastogenesis from human monocytes; possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 44 (2001) 1003-1012
33. Gravallese E.M., et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 43 (2000) 250-258
34. Shigeyama Y., et al. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum. 43 (2000) 2523-2530
35. Crotti T., et al. Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis and from normal patient; semiquantitative and quantitative analysis. Ann. Rheum. Dis. 61 (2002) 1047-1054
36. Haynes D.R., et al. Osteoprotegerin and receptor activator of nuclear factor kB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 40 (2001) 623-630
37. Guesens P.P., et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum. 54 (2006) 1772-1777
38. Anandarajah A.P., et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow edema in patients with psoriatic arthritis. Ann. Rheum. Dis. 67 (2008) 296-301
39. Ritchlin C.T., et al. Mechanisms of anti-TNF-alpha and RANKL mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest. 111 (2003) 821-831
40. Vandooren B., et al. The abundant synovial expression of the RANK/ RANKL/ osteoprotegerin system in peripheral spondyloarthropathies is partially disconnected from inflammation. Arthritis Rheum. 58 (2008) 718-729
41. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27 (2001) 165-176
42. Guise T.A., et al. Molecular mechanisms of breast cancer metastases to bone. Clin. Breast Cancer 5 (2005) S46-S53
43. Mountzios G., et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator nuclear factor-kB ligand (RANKL)/ osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol. (Madr.) 45 (2007) 221-229
44. Roux S., and Mariette X. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor kappa B) and RANK ligand expression. Leuk. Lymphoma 45 (2004) 1111-1118
45. Lai F.P., et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br. J. Haematol. 126 (2004) 192-201
46. Farrugia A.N., et al. Receptor activator of nuclear factor kB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res. 63 (2003) 5438-5445
47. Ulrich-Vinther M., and Andreassen T.T. Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. Calcif. Tissue Int. 76 (2005) 280-286
48. Flick L.M., et al. Effects of receptor activator of NFkB (RANKL) signaling blockade on fracture healing. J. Orthop. Res. 21 (2003) 676-684
49. Looney R.J., et al. Periprosthetic osteolysis: an immunologist's update. Curr. Opin. Rheumatol. 18 (2006) 80-87
50. Min H., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J. Exp. Med. 192 (2000) 463-474
51. Vega D., et al. The Role of Receptor activator of nuclear factor-kB (RANK), RANK ligand/ Osteoprotegerin: clinical implications. J. Clin. Endocrinol. Metab 92 (2007) 4514-4521
52. Kostenuik P.J., et al. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 34 (2004) 656-664
53. Capparelli C., et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J. Bone Miner. Res. 18 (2003) 852-858
54. Bekker P.J., et al. Osteoprotegerin (OPG) has potent and sustained antiresorptive activity in postmenopausal women. J. Bone Miner. Res. 16 (2001) 348-360
55. Body J.J., et al. A phase I study of AMG-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinomas related bone metastases. Cancer 97 (2003) 887-892
56. Anandarajah A.P., and Schwarz E.M. Anti-RANKL therapy for inflammatory bone disorders: mechanisms and Potential clinical applications. J. Cell. Biochem. 97 (2006) 226-232
57. Bekker P.J., et al. A single-dose placebo-controlled study of AMG-162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19 (2004) 1059-1066
58. Lewiecki E.M., et al. Two-year treatment with denosumab (AMG-162) in a randomized phase 2 study of postmenopausal women with low BMD. J. Bone Miner. Res. 22 (2007) 1832-1841
59. Bone H.G., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab. 93 (2008) 2149-2152
60. Redlich K., et al. Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 46 (2002) 785-792
61. Schett G., et al. Additive bone protective effects of anabolic treatment when used in combination with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum. 52 (2005) 1604-1611
62. Cohen S.B., et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 58 (2008) 1299-1309
63. Body J.J., et al. A study of the biological receptor activator of nuclear factor-kB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res. 12 (2006) 1221-1228